In conclusion, our results implicate CD59 as an important regulator in NMO pathogenesis and potentially a new drug target with a novel mechanism of action to reduce complement-mediated astrocyte damage, a key initiating event in NMO. The gene discussed is CD59; the disease is neuromyelitis optica.